These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15767826)

  • 1. Lessons learned from the COX-2 advisory hearings.
    Somberg J
    Am J Ther; 2005; 12(2):105. PubMed ID: 15767826
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 3. Raising the safety bar--the FDA's coxib meeting.
    Okie S
    N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA labors over NSAID decisions: panel suggests COX-2 inhibitors stay available.
    Young D
    Am J Health Syst Pharm; 2005 Apr; 62(7):668-72. PubMed ID: 15790792
    [No Abstract]   [Full Text] [Related]  

  • 5. The politics of therapeutics.
    Somberg J
    Am J Ther; 2004; 11(6):422. PubMed ID: 15543080
    [No Abstract]   [Full Text] [Related]  

  • 6. How to avoid another 'Vioxx'.
    Frantz S
    Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595
    [No Abstract]   [Full Text] [Related]  

  • 7. Learning the value of drugs--is rofecoxib a regulatory success story?
    Eisenberg RS
    N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety, scrutiny and conflicts: assessing the fallout and lessons learned from pharmaceuticals.
    Lanzafame RJ
    Photomed Laser Surg; 2005 Feb; 23(1):1-2. PubMed ID: 15782023
    [No Abstract]   [Full Text] [Related]  

  • 9. The coxib conundrum: lessons from the rise and fall of rofecoxib.
    Whelton A
    Am J Ther; 2004; 11(6):417-21. PubMed ID: 15543079
    [No Abstract]   [Full Text] [Related]  

  • 10. Delays and difficulties in assessing metal-on-metal hip implants.
    Rising JP; Reynolds IS; Sedrakyan A
    N Engl J Med; 2012 Jul; 367(1):e1. PubMed ID: 22716934
    [No Abstract]   [Full Text] [Related]  

  • 11. Retesting and laboratory investigations.
    Davis JS
    J Pharm Sci Technol; 1994; 48(3):107-9. PubMed ID: 8069512
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. US FDA contemplates collection of pharmacogenomic data.
    Kling J
    Nat Biotechnol; 2003 Jun; 21(6):590. PubMed ID: 12776133
    [No Abstract]   [Full Text] [Related]  

  • 14. Painful lessons.
    Nat Rev Drug Discov; 2005 Oct; 4(10):800-3. PubMed ID: 16237842
    [No Abstract]   [Full Text] [Related]  

  • 15. The unfinished business of U.S. drug safety regulation.
    Evans BJ; Flockhart DA
    Food Drug Law J; 2006; 61(1):45-63. PubMed ID: 16838457
    [No Abstract]   [Full Text] [Related]  

  • 16. EU directive on clinical trials penalizes small sponsors.
    Meldolesi A
    Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
    [No Abstract]   [Full Text] [Related]  

  • 17. The lessons of Vioxx.
    Frazier KC
    N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
    [No Abstract]   [Full Text] [Related]  

  • 19. What are the real lessons from Vioxx?
    Edwards IR
    Drug Saf; 2005; 28(8):651-8. PubMed ID: 16048352
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceutical postmarket review: fact or fiction?
    Schanz SJ
    Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.